Drug Interaction Report
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- ticagrelor
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:ticagrelor trofinetide
Applies to: ticagrelor, trofinetide
Trofinetide may increase the blood levels and effects of ticagrelor.
Talk to your doctor if you have any questions or concerns.
You may need more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle ticagrelor
Applies to: ticagrelor
Grapefruit juice may increase the blood levels of ticagrelor and may increase the risk of bleeding complications.
Talk to your doctor if you have any questions or concerns.
Call your doctor promptly if you experience any unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, dizziness, or weakness during treatment.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactionsApplies to: 6 conditions, including Peptic Ulcer, Hemodialysis, Liver Disease, Bleeding Disorder, and Sinus Node Dysfunction.
Bleeding Disorder
Major:ticagrelor
Ticagrelor has a major potential interaction with Bleeding Disorder.
Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
Hemodialysis
Moderate:ticagrelor
Ticagrelor has a moderate potential interaction with Hemodialysis.
No dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied, close monitoring is recommended.
Liver Disease
Major:ticagrelor
Ticagrelor has a major potential interaction with Liver Disease.
Ticagrelor is metabolized by the liver. The use of ticagrelor should be avoided in patients with severe hepatic impairment. Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment.
Peptic Ulcer
Major:ticagrelor
Ticagrelor has a major potential interaction with Peptic Ulcer.
Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
Pulmonary Impairment
Moderate:ticagrelor
Ticagrelor has a moderate potential interaction with Pulmonary Impairment.
Dyspnea has been reported with the use of ticagrelor. Care should be taken when prescribing this drug to patients that experienced dyspnea. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible. In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.
Sinus Node Dysfunction
Moderate:ticagrelor
Ticagrelor has a moderate potential interaction with Sinus Node Dysfunction.
Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the postmarketing setting. It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.